




The relative strengths and weaknesses of Midatech Pharma US Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Midatech Pharma US Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Midatech Pharma US Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 299%, being 45% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	13,774
Cost of Goods Sold	0
Intangible Assets	3,930
Liabilities, Current	3,745
Liabilities, Non-Current	0
Other Assets	13
Other Compr. Net Income	0
Other Expenses	6,306
Other Liabilities	91
Other Net Income	163
Other Revenues	1,887
Property and Equipment	36
Research and Development	476
Selling, General and Administrative Expense	4,505

Output Variable	Value in 1000 USD
Assets	17,752
Liabilities	3,836
Expenses	11,287
Revenues	1,887
Stockholders Equity	13,916
Net Income	-9,237
Comprehensive Net Income	-9,237
BaseVar	17,462
ECR before LimitedLiability	195%
Economic Capital Ratio	299%